Two French companies have joined forces to co-develop manufacturing technologies for AAV-based gene therapies. Coave Therapeutics is to contribute its expertise on viral vectors to the collaboration, while ABL, a contract development and manufacturing organisation, will provide production skills and laboratory space in Lyon.
